Highlights from the EBMT Annual Meeting Impact of the Treatment Sequence of Glofitamab and CAR-T Therapy on Efficacy, Survival, and Target Antigen Expression in Relapsed/Refractory B-NHL 

Highlights from the EBMT Annual Meeting Impact of the Treatment Sequence of Glofitamab and CAR-T Therapy on Efficacy, Survival, and Target Antigen Expression in Relapsed/Refractory B-NHL 

The 52nd EBMT Annual Meeting will take place in Madrid, Spain, from March 22 to 25, 2026. As one of the most influential international meetings in hematopoietic stem cell transplantation and cellular therapy, the congress brings together more than 6,000 experts from over 90 countries and regions to discuss advances in basic research, clinical translation, optimization of transplant strategies, and innovation in cellular therapies.
Voices from China at the EBMT Annual Meeting Prof. Xingyu Cao & Bixin Li: Efficacy and Safety of PD-1 Inhibitors in Acute Leukemia Patients with MRD Positivity After Allogeneic HSCT

Voices from China at the EBMT Annual Meeting Prof. Xingyu Cao & Bixin Li: Efficacy and Safety of PD-1 Inhibitors in Acute Leukemia Patients with MRD Positivity After Allogeneic HSCT

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the central challenges in the treatment of acute leukemia. Minimal residual disease (MRD) positivity serves as an important early warning signal for relapse, and identifying effective interventions during this critical window has become a major focus of clinical research.
Highlights from the EBMT Annual Meeting CD19 CAR-T Therapy in Transformed Follicular Lymphoma: A Real-World Cohort of 43 Patients 

Highlights from the EBMT Annual Meeting CD19 CAR-T Therapy in Transformed Follicular Lymphoma: A Real-World Cohort of 43 Patients 

The 52nd EBMT Annual Meeting will be held in Madrid, Spain, from March 22 to 25, 2026. As one of the most prominent international meetings in hematology, EBMT brings together experts from around the world to discuss cutting-edge advances in hematopoietic stem cell transplantation and cellular therapies, driving innovation in clinical practice.
Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study 

Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study 

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the leading international forums in hematology, the meeting brings together experts worldwide to present advances in transplantation, cellular immunotherapy, and complication management, and remains an important platform shaping the future of hematologic treatment.
EAU26 Afternoon Dialogue | Prof. Kan Gong: Large-Scale Chinese VHL Cohort Reveals Distinct Mutation Patterns and Clinical Implications 

EAU26 Afternoon Dialogue | Prof. Kan Gong: Large-Scale Chinese VHL Cohort Reveals Distinct Mutation Patterns and Clinical Implications 

The 2026 European Association of Urology Annual Congress (EAU26), held in London, once again served as a premier platform showcasing cutting-edge advances in urologic oncology. At this year’s meeting, Prof. Kan Gong and his team from Peking University First Hospital presented a series of impactful studies focusing on von Hippel–Lindau (VHL) syndrome–associated renal cell carcinoma in the Chinese population.
Voices from China at the EBMT Annual Meeting丨Prof. Yue Lu / Prof. Fang Xu: Efficacy and Safety of Blinatumomab as Part of Induction or Early Consolidation Therapy in Newly Diagnosed B-Cell Acute Leukemia

Voices from China at the EBMT Annual Meeting丨Prof. Yue Lu / Prof. Fang Xu: Efficacy and Safety of Blinatumomab as Part of Induction or Early Consolidation Therapy in Newly Diagnosed B-Cell Acute Leukemia

Blinatumomab, a CD19/CD3 bispecific antibody, has demonstrated clear efficacy in relapsed/refractory and MRD-positive B-cell acute lymphoblastic leukemia (B-ALL). Its integration into frontline therapy for newly diagnosed patients is now being actively explored and may reshape treatment paradigms.
Voices from China at the EBMT Annual Meeting丨Prof. Peihua Lu / Prof. Wei Zhao: Letermovir Prophylaxis Reshapes Early Immune Reconstitution and CMV/EBV Reactivation Dynamics After Allogeneic HSCT

Voices from China at the EBMT Annual Meeting丨Prof. Peihua Lu / Prof. Wei Zhao: Letermovir Prophylaxis Reshapes Early Immune Reconstitution and CMV/EBV Reactivation Dynamics After Allogeneic HSCT

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the most influential global conferences in hematopoietic stem cell transplantation, the meeting showcased cutting-edge research and the latest clinical advances in the field.
Voices from China at the EBMT Annual Meeting丨Prof. Hui Wang: An Early Myeloid Stem/Progenitor Cell–Based Immunophenotypic Panel Enables Rapid and Efficient Differentiation of APL from APL-Like AML

Voices from China at the EBMT Annual Meeting丨Prof. Hui Wang: An Early Myeloid Stem/Progenitor Cell–Based Immunophenotypic Panel Enables Rapid and Efficient Differentiation of APL from APL-Like AML

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. The conference focused on the latest advances in clinical hematology and hematopoietic stem cell transplantation, promoting continued progress in both clinical practice and translational research.
Voices from China at the EBMT Annual Meeting丨Liu Deyan / Liu Xiaohong: Efficacy of Gemtuzumab Ozogamicin in Relapsed/Refractory AML After Allo-HSCT and Outcomes of Bridging to Second/Third Transplantation — A Retrospective Study

Voices from China at the EBMT Annual Meeting丨Liu Deyan / Liu Xiaohong: Efficacy of Gemtuzumab Ozogamicin in Relapsed/Refractory AML After Allo-HSCT and Outcomes of Bridging to Second/Third Transplantation — A Retrospective Study

Relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) carries an extremely poor prognosis, particularly in patients with high CD33 expression who are refractory to conventional salvage therapies, where treatment options remain very limited.